Open

Relapsed and Refractory CLL, SLL, and Select Low-grade Lymphomas Treatment Study

In this study, we are looking at a medicine called ZE50-0134 that might help treat people with relapsed and refractory CLL, SLL, or certain low-grade lymphomas. We want to see if taking different amounts of this medicine in capsule form is safe for patients.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

The study involves questionnaires, physical examination, urine and blood tests, ECG, and pregnancy testing. The study also involves CT or MRI scan, bone marrow aspirate/biopsy, Biomarker research, and study drugs.

Incentives

Study Medication, Travel Reimbursement

In-person visits:
0-20+

Phone or online visits:
0-20+

Total length of participation:
24 months

Looking for Specific Volunteers

Able to participate:

You have functioning bone marrow, liver, and renal
You have received at least 2 or more therapies that have included BTKi and venetoclax
You are willing to use highly effective contraception

Not eligible if:

You have been diagnosed with known active Richter's transformation
You have known active CMV, HBV, HCV
You have been diagnosed with clinically significant cardiac disease
You have an active clinically serious infections that is requiring treatment with IV medications
You have had an allogeneic bone marrow transplant within 4 months before starting the study medication

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Comprehensive Cancer Center
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Deborah Stephens
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Lymphoma)

IRB Number

25-0277

ClinicalTrials.gov

NCT06708897

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.